{
  "docId": "019de075-12bd-74a7-bc75-4587e4948a57",
  "docSlug": "9c54f748d4238e6a3a690a4101a45e99",
  "documentTitle": "Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 50,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 28,
  "notes": "Includes a testimonial quote from a US KOL.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-12bd-74a7-bc75-4587e4948a57/14",
  "deckHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57",
  "deckJsonHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57.json",
  "deckAnchorHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "chart",
      "text": "Entyvio Global sales (2014-28F)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74a5a442-d104-41dc-9ac1-944d305432a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.52,
        "y": 0.4
      },
      "kind": "chart",
      "text": "Entyvio US/EU % market share (June 2014-June 2022)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ccbbf07c-3510-4853-a58f-861f61517192",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Vedolizumab estimated $5.4B revenues WW in FY22. Projected to sell $7.5-9.0B at peak WW.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "89be4d05-a398-4883-b64f-846fff238744",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.5,
        "y": 0.25
      },
      "kind": "list",
      "text": "Significant market share: ~36% of UC market share and ~20% of CD market share in US.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9b80e08-8c6f-412f-820e-019728c6c9be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.3,
        "y": 0.15
      },
      "kind": "quote",
      "text": "“Biologic of choice is Entyvio.” – US KOL",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d21bedb2-1105-4f98-99c1-33d386fc7810",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "1. Takeda JPM 2023 presentation. Note that Takeda’s FY22 is April 2022-March 2023. Sales forecast in figure: EvaluatePharma consensus",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2bbb1ff-4e24-4146-9024-094282a265c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Vedolizumab is a mega-blockbuster product in IBD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e827e982-e870-437e-a468-a6fe592bfb27",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}